Individuals who undergo frequent aesthetic treatments such as microneedling, laser, peels, or dermaplaning often find that GHK-Cu peptides significantly reduce downtime, redness, and inflammation while accelerating recovery
This reduction directly impacts the synthesis of Insulin-like Growth Factor 1 (IGF-1) in the liver, leading to systemic changes in tissue repair, cellular regeneration, and metabolic efficiency
Research into GHK-Cu benefits goes back decades, with published findings on: Skin firmness and texture appearance Hair density and fullness Fine line visibility All promising
These drugs make it unmistakably clear that appetite and weight are deeply biological
2016
[2] Novo Nordisk and Eli Lilly Globally, the GLP-1 medications market is controlled by two major pharmaceutical companies, U.S.-based Eli Lilly and Denmark-based Novo Nordisk